The Food and Drug Administration (FDA) is highlighting its scientific review into marijuana that led the agency to recommend rescheduling—a process that involved a comprehensive analysis of research, as well looking at hundreds of posts on social media platforms to see how consumers described cannabis’s therapeutic impact. In its 2023 fiscal year Drug Safety Priorities […]
The Food and Drug Administration (FDA) is highlighting its scientific review into marijuana that led the agency to recommend rescheduling—a process that involved a comprehensive analysis of research, as well looking at hundreds of posts on social media platforms to see how consumers described cannabis’s therapeutic impact. In its 2023 fiscal year Drug Safety Priorities Read More CANNABIS, MARIJUANA, SOCIAL MEDIA